☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

MeReC Extra 52

The National Prescribing Centre has published MeReC Extra 52 (PDF) which discusses the results of the recently published SATURN study and recent safety warnings issued for citalopram, escitalopram and dabigatran.

The SATURN Study compared two high intensity statins in 1,385 patients with cardiovascular disease and assessed atherosclerotic plaque volume. At the end of the 2 year study there was no difference in this primary outcome with atorvastatin 80mg reducing plaque volume by 0.99% (95% CI −0.63 to -1.19) and rosuvastatin 40mg by 1.22% (95% CI -0.90 to -1.52). It is unknown whether this reduction in plaque volume would lead to a reduction in the risk of cardiovascular events. It is therefore suggested that clinicians continue to follow national guidance and use simvastatin 40mg for the majority of individuals here statin therapy is required.

The recently reported safety warnings regarding a dose dependent prolongation QT interval with citalopram and escitalopram and the new requirement to assess renal function before starting treatment with dabigatran and during therapy in some patients are also discussed.

Action: Clinicians who prescribe, or who see patients who are prescribed, any of these drugs will find this information useful and informative.

Share 'MeReC Extra 52' on Email Share 'MeReC Extra 52' on Delicious Share 'MeReC Extra 52' on Digg Share 'MeReC Extra 52' on Facebook Share 'MeReC Extra 52' on reddit Share 'MeReC Extra 52' on Twitter


No Comments to “MeReC Extra 52”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.